Latest news with #DXCM
Yahoo
6 days ago
- Business
- Yahoo
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change
We recently published . DexCom, Inc. (NASDAQ:DXCM) is one of the companies that stood stronger last week. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to close at $76.25 apiece as investors turned cautious following the announcement of a leadership change after the company's strong earnings performance in the second quarter of the year. In a statement last week, DexCom, Inc. (NASDAQ:DXCM) named Jake Leach as its new chief executive officer (CEO) effective January 1, 2026, in addition to his post as the current president and chief operating officer. Incumbent CEO Kevin Sayer will continue to work closely with Leach during the transition period and remain executive chairman of the board of directors. Meanwhile, DexCom, Inc. (NASDAQ:DXCM) grew its net income in the second quarter of the year by 25 percent to $179.8 million from $143.5 million in the same period last year. Revenues increased by 16 percent to $1.16 billion from $1 billion year-on-year. While we acknowledge the potential of DXCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-07-2025
- Business
- Yahoo
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
The upcoming report from DexCom (DXCM) is expected to reveal quarterly earnings of $0.45 per share, indicating an increase of 4.7% compared to the year-ago period. Analysts forecast revenues of $1.12 billion, representing an increase of 11.8% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts. Analysts forecast 'Revenue- Hardware' to reach $38.99 million. The estimate indicates a year-over-year change of -32%. It is projected by analysts that the 'Revenue- Sensor and other' will reach $1.08 billion. The estimate suggests a change of +14.5% year over year. According to the collective judgment of analysts, 'Revenue- United States' should come in at $809.70 million. The estimate indicates a change of +10.6% from the prior-year quarter. The combined assessment of analysts suggests that 'Revenue- International' will likely reach $311.29 million. The estimate indicates a year-over-year change of +14.3%. View all Key Company Metrics for DexCom here>>> Over the past month, DexCom shares have recorded returns of +3.1% versus the Zacks S&P 500 composite's +4.9% change. Based on its Zacks Rank #2 (Buy), DXCM will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
30-07-2025
- Health
- Business Wire
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.* Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes 1. This highlights a broad need for support across both types of diabetes for insulin therapy optimization. This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario †,2 for people on insulin through the following programs: Ontario Drug Benefit (ODB) – for eligible residents on insulin aged 65+ or earlier if they: Live in a long-term care home, home for special care, or Community Home for Opportunity Are 24 or under without private insurance (OHIP+) Receive professional home and community care Get benefits from Ontario Works or ODSP Are enrolled in the Trillium Drug Program Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet the eligibility criteria. Private Insurance – most private insurance plans cover Dexcom G7 for anyone on insulin. – for eligible First Nations and Inuit clients on insulin. 'This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom's life-changing CGM technology,' says André Côté, Vice President and General Manager of Dexcom Canada. 'By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists ‡, 3 for the management of insulin-using patients.' Dexcom G7 is the most accurate CGM with clinically proven outcomes §,2 including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes 4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin. 'As an endocrinologist, I've seen firsthand how continuous glucose monitoring has transformed diabetes management,' says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. 'Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical.' Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time. Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle: Predictive Urgent Low Soon || alert that can warn in advance of severe hypoglycemia 9 Delay 1 st High alert after a meal that may help reduce insulin stacking 10,11 Waterproof sensor ¶ Fast 30-minute sensor warm-up time Multiple sensor wear locations # Direct to Apple Watch functionality ** – user can see glucose numbers right on their wrist As the #1 patient recommended CGM in Canada ††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management. To learn more about Dexcom G7 and the public and private coverage options available, please visit About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR _______________________________________ * For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit † Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions. ‡ Based on a survey of Canadian Endocrinologists (n=41) § When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen. || Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes. ¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. # Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old. ** Smart device sold separately. To view a list of compatible devices, visit Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. †† Based on a comparison in NPS scores across major CGM brands 1 2 Dexcom, data on file, 2025 3 Q&A, Dexcom Canadian Endos Report Wave 1 2024 4 Beck, RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Dexcom G7 User Guide. 10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255. 11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158. 12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024 Expand
Yahoo
07-07-2025
- Business
- Yahoo
What You Need to Know Ahead of DexCom's Earnings Release
DexCom, Inc. (DXCM), a San Diego-based medical device company with a $32.5 billion market cap, specializes in continuous glucose monitoring (CGM) systems. Its technology includes a small, implantable sensor that tracks glucose levels beneath the skin and transmits data to an external receiver in real-time. DexCom is slated to report its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30. Ahead of the event, analysts expect DXCM to report a profit of $0.45 per share on a diluted basis, up 4.7% from $0.43 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions. Chevron Stock's 4.6% Dividend Yield and 1.67% One Month Short Put Yield Make CVX a Buy Tariff Dealine, Fed Minutes and Other Key Thing to Watch this Week SoFi Stock Is Betting on Crypto Again. How Should You Play SOFI Stock Here? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect DXCM to report EPS of $2.03, up 23.8% from $1.64 in fiscal 2024. Its EPS is expected to rise 24.6% year over year to $2.53 in fiscal 2026. Over the past 52 weeks, DXCM's shares have dipped 25.2%, underperforming the S&P 500's ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund's (XLV) 5.4% dip over the same time frame. On July 1, DexCom shares fell over 4% after the U.S. government proposed changes to payment schedules and introduced a competitive bidding program for diabetes devices, impacting the broader glucose monitoring and insulin pump sector. Nevertheless, analysts' consensus opinion on DXCM stock is very positive, with an overall 'Strong Buy' rating. Out of 25 analysts covering the stock, 20 advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' and four give a 'Hold.' DXCM's average analyst price target is $99.68, indicating a potential upside of 20.2% from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. DexCom is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 0.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that DXCM has returned about 7.5% since the start of the calendar year. In comparison, Medical companies have returned an average of -2.9%. This shows that DexCom is outperforming its peers so far this year. One other Medical stock that has outperformed the sector so far this year is Bayer Aktiengesellschaft (BAYRY). The stock is up 59.4% year-to-date. The consensus estimate for Bayer Aktiengesellschaft's current year EPS has increased 6.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 84 individual stocks and currently sits at #186 in the Zacks Industry Rank. This group has lost an average of 7.5% so far this year, so DXCM is performing better in this area. Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 10-stock industry is ranked #53. The industry has moved -0.3% so far this year. Investors with an interest in Medical stocks should continue to track DexCom and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research 登入存取你的投資組合
